Treatment of HIV-associated primary CNS lymphoma with antiretroviral therapy, rituximab, and high-dose methotrexate
Kathryn Lurain(The Ohio State University), Robert Yarchoan(National Cancer Institute), Mary Anne Tamula(Leidos (United States)), Seth M. Steinberg(National Institutes of Health), Staci Martin(National Institutes of Health), Thomas S. Uldrick(Regeneron (United States)), Richard F. Little(Dana-Farber Cancer Institute), Mark N. Polizzotto(AIDS United), Pamela L. Wolters(National Cancer Center), Anaida Widell(AIDS United), Ramya Ramaswami(National Cancer Institute), Elaine S. Jaffe(National Cancer Institute), Hao‐Wei Wang(Fu Jen Catholic University), Jomy George(National Institutes of Health), Stefania Pittaluga(New York University), Priscila Gonçalves(The Barbara Ann Karmanos Cancer Institute), Constance M. Yuan(National Cancer Institute)
Cited by 45
Related Papers
The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma
|New England Journal of Medicine|2002|3.9k
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2018|2.3k
The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications
|Blood|2011|2k
Stromal Gene Signatures in Large-B-Cell Lymphomas
|New England Journal of Medicine|2008|1.8k